CBC — cannabichromene, the underrated compound
After CBD, CBC is one of the most abundant non-psychoactive cannabinoids — yet barely known. What it does, and why it matters.
CBC barely binds CB1/CB2 but strongly activates TRPV1 and TRPA1 — pain and inflammation receptors. Early research shows mood and neurogenic effects. Always present in full-spectrum — rarely standalone.
What is CBC?
CBC = cannabichromene, known since 1966. Forms via CBGA → CBCA, decarboxylated by heat. Non-psychoactive even at high doses.
Activates TRPV1 (pain/heat) and TRPA1 (inflammation), inhibits anandamide reuptake — boosting natural endocannabinoid action.
Effect profile
Anti-inflammatory: in vitro comparable to phenylbutazone. Useful in skin topicals.
Mood-regulating: antidepressant signal in animal models (Rock et al., 2018).
CBC in products
Rarely isolated — mostly in full-spectrum extracts. Specialty CBC-CBG-CBD blends exist for wellness and skincare.
High-CBC genetics rare; classic strains contain 0.1–0.5%.
FAQ
Is CBC psychoactive?
No.
CBC vs CBD?
CBD broad, well studied. CBC specific: pain, inflammation, mood. Complementary.
Where to find CBC?
In any good full-spectrum. Rare as standalone.
Legal in Switzerland?
Yes, < 1% THC in final product.
Side effects?
Barely documented. Well tolerated.